Pharmaceutical News

RSS

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences Corporation, manufacturer of the revolutionary Flublok influenza vaccine, announced today that doses of the vaccine have been released and are now available for shipment.

29 Sep 2014

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer.

29 Sep 2014

Study correlates HPV vaccine series completion among young US women

According to a recent study in the journal Human Vaccines & Immunotherapeutics, only 60% of young US women who received the first dose of the human papilloma virus (HPV) vaccine went on to complete the three-dose vaccine series.

29 Sep 2014

NJHF awards grant to help launch drug discovery facility at Rutgers University

In its continuing effort to advance the biomedical sciences, New Jersey Health Foundation has awarded a pivotal $35,000 grant to the Office of Translational Sciences at Rutgers, The State University of New Jersey, to help launch a Fragment Based Drug Discovery (FBDD) core facility.

29 Sep 2014

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).

27 Sep 2014

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

An interdisciplinary team of researchers from the University of Vienna (Institute of Inorganic Chemistry) and the Medical University of Vienna (Institute for Cancer Research) has successfully developed a new strategy for reducing the often serious side effects of an important class of modern anticancer drugs (tyrosine kinase inhibitors).

26 Sep 2014

AcelRx plans for resubmission of Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso (sufentanil sublingual tablet system).

26 Sep 2014

Access to potentially life-extending cancer drugs varies worldwide

Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain.

26 Sep 2014

International organizations join forces to develop inhaled form of oxytocin for postpartum hemorrhage

An international group of public and private organizations is collaborating to accelerate development of an innovative heat-stable and low-cost inhaled form of oxytocin to manage postpartum hemorrhage in resource-poor settings.

26 Sep 2014

Sumitomo Dainippon Pharma, SanBio to jointly develop SB623 in the U.S. and Canada

Sumitomo Dainippon Pharma Co., Ltd. and SanBio Co., Ltd., acting through its U.S. subsidiary SanBio, Inc., announced on September 26 that the two companies have entered into a joint development and license agreement for exclusive marketing rights in the U.S. and Canada ("Agreement") for SB623, a cell therapy for the treatment of patients with chronic stroke discovered and currently under development by SanBio.

26 Sep 2014

IGI Laboratories acquires regulatory rights for 18 drug products from AstraZeneca

IGI Laboratories, Inc., a New Jersey based specialty generic pharmaceutical company, today announced it has acquired the regulatory rights and related documents and records for 18 drug products from AstraZeneca, 17 of which were marketed.

25 Sep 2014

CorMedix submits IND application to FDA for Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin was submitted to the United States Food and Drug Administration on Wednesday, September 24, 2014.

25 Sep 2014

AAC issues safety message to consumers about cold and flu medicines

As the countdown to cold and flu season begins, consumers are getting flu shots and increasing their purchases of cold and flu medicines. The Acetaminophen Awareness Coalition is issuing a safety message to consumers, reminding them to double check their medicine labels to avoid doubling up on medicines with acetaminophen when treating symptoms during the upcoming cold and flu season.

25 Sep 2014

New CRUK-MEDI Alliance Laboratory to focus on development of novel biologic cancer treatments

CANCER RESEARCH UK, with its commercial arm Cancer Research Technology, today announce that they have entered into an innovative collaboration with AstraZeneca and MedImmune, its global biologics research and development arm, to establish a joint laboratory in Cambridge, UK.

25 Sep 2014

Research findings open up new avenues for development of chronic itch treatments

Areas of the brain that respond to reward and pleasure are linked to the ability of a drug known as butorphanol to relieve itch, according to new research led by Gil Yosipovitch, MD, Professor and Chairman of the Department of Dermatology at Temple University School of Medicine, and Director of the Temple Itch Center.

25 Sep 2014

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Sep 2014

New findings raise hope for novel class of drugs to treat lupus

New findings by a biomedical engineer and his team at the University of Houston raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease.

25 Sep 2014

Research report on biopharmaceutical and vaccine manufacturing markets

The total biopharmaceutical manufacturing market is growing, according to Kalorama Information's report, Biopharmaceutical and Vaccine Production Markets.

24 Sep 2014

Capital Bluecross encourages people to make use of National Prescription Drug Take-Back Day

To support a nationwide effort to clear homes of potentially dangerous, expired, unused and unwanted prescription drugs, Capital BlueCross is reminding residents to take advantage of the Drug Enforcement Administration's (DEA) National Prescription Drug Take-Back Day from 10 a.m. to 2 p.m. Saturday, Sept. 27. Take-Back Day collection is free and anonymous.

24 Sep 2014

Leicester scientists lend a helping hand in fight against Alzheimer's and cancer

Chemists at the University of Leicester have reported a breakthrough in techniques to develop new drugs in the fight against diseases such as cancer and Alzheimer's.

24 Sep 2014

Pharmaceutical News

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

Study correlates HPV vaccine series completion among young US women

NJHF awards grant to help launch drug discovery facility at Rutgers University

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

AcelRx plans for resubmission of Zalviso NDA

Access to potentially life-extending cancer drugs varies worldwide

International organizations join forces to develop inhaled form of oxytocin for postpartum hemorrhage

Sumitomo Dainippon Pharma, SanBio to jointly develop SB623 in the U.S. and Canada

IGI Laboratories acquires regulatory rights for 18 drug products from AstraZeneca

CorMedix submits IND application to FDA for Neutrolin

AAC issues safety message to consumers about cold and flu medicines

New CRUK-MEDI Alliance Laboratory to focus on development of novel biologic cancer treatments

Research findings open up new avenues for development of chronic itch treatments

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

New findings raise hope for novel class of drugs to treat lupus

Research report on biopharmaceutical and vaccine manufacturing markets

Capital Bluecross encourages people to make use of National Prescription Drug Take-Back Day

Leicester scientists lend a helping hand in fight against Alzheimer's and cancer

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News